Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study].

"Conflict of Interest E.L. reports research grants from Janssen, Pfizer and Takeda; educational grants from AbbVie, Janssen and Takeda; speaker fees from AbbVie, Celgene, Falk, Ferring, Janssen, Pfizer, Roche and Takeda; consultancy fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Galapagos, Gilead, Janssen and Takeda. C.A.S. reports consultancy fees from AbbVie, BMS, Janssen, Lilly, Pfizer, Prometheus and Takeda; speaker fees from Continuing Medical Education activities for AbbVie, BMS, Pfizer and Takeda; research grants from AbbVie, Janssen, Pfizer, and Takeda. B.J. is an employee of AbbVie and may own stock and/or options. S.H. and N.K. are employees of Evidera, a business unit of Pharmaceutical Product Development, LLC. Evidera received funding for conducting the work outlined in this paper. S.H. is a minority stockholder of Thermo Fisher Scientific as part of his employment. S.G. reports speaker fees from AbbVie, Janssen, Pfizer and Takeda; consultancy fees from Boehringer Ingelheim, Celgene, Eli Lilly, Gilead and Roche; is a steering committee member for AbbVie, Boehringer Ingelheim, Celgene and Janssen; and is an advisory committee member for AbbVie."

"Funding This work was supported by AbbVie."